Navigation Links
Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
Date:7/22/2013

pan>/Australia, and China. 

Recently, Kinex has received US FDA allowance on the KX02 IND, a program that Kinex has partnered with Xiangxue Pharmaceuticals for the greater China Territory.  Through their collaboration with Hanmi, one of Kinex's internally developed compounds, KX01, is also currently in clinical trials in both the USA and Korea in a variety of indications. 

Dr. Lyn Dyster, Senior Vice President of Operations, stated, "Working with the Hanmi team on the Oraxol IND has been terrific.  Their expertise and dedicated team, combined with our internal efforts, lead to a timely IND submission.  Given that Hanmi is in Phase II in Korea, their extensive preclinical and clinical knowledge of the compound was invaluable to our efforts.  Oraxol is an important program for both companies and we are excited to move forward with our clinical programs in the United States."

"The allowance of the Oraxol IND by the US FDA is a major step in our global development strategy," added Dr. Rudolf Kwan, Chief Medical Officer of Kinex.  "Combined with Hanmi's significant Oraxol clinical efforts in Korea and the potential for trials in New Zealand to begin in the near future, we are on track to leverage our team's combined infrastructure and development capabilities on a global basis.  We believe this approach will produce meaningful data in the most time efficient manner. I am very excited with this program."

Dr. Gwan Sun Lee, Chief Executive Officer of Hanmi Pharmaceutical said, "The Kinex team moved the IND process forward in a precise and expert manner. This is another major step forward in the collaboration between Kinex and Hanmi.  I believe that as part of our global growth strategy, our partnership wit
'/>"/>

SOURCE Kinex Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
2. Kinex Announces that the US FDA Allows their IND to Begin KX02 Clinical Trials
3. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
4. Kinex Pharmaceuticals Chief Scientific Officer, Dr. David Hangauer, named the American Cancer Societys 2013 Honoree for its Cuisine for a Cure event
5. Hanmi and Kinex Announced Korean FDA Allowance of the KX01 IND Application
6. Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations
7. Kinex Pharmaceuticals Receives Substantial Strategic Investment
8. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
9. ANI Pharmaceuticals, Inc. Announces Date for Second Quarter 2013 Earnings Release
10. QRxPharma Announces Collaboration With Aesica
11. FDAnews Announces Leading the Climb: Seven Essentials of GMP Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  ConvaTec, a privately-held medical ... Clerkin has been appointed chief financial officer of ... Clerkin was previously executive vice president and chief financial ... -based biotechnology company.  Mr. Clerkin was part of a ... Elan, culminating in its sale to Perrigo, a pharmaceutical ...
(Date:7/22/2014)... , July 22, 2014  UL (Underwriters ... that the U.S. Food and Drug Administration (FDA) ... consensus standards for medical devices incorporating lithium or ... - Standard for Household and Commercial Batteries, and ... Consensus standards are standards recognized ...
(Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - Curis, ... novel targeted,medicines primarily for cancer treatment, today ... presentations at the 98th Annual Meeting,of the ... AACR, Curis also disclosed that its April ...
... 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the ... clinical trial of the triplet combination of ... the,first-line treatment of advanced non-small cell lung ... significant,improvement in both progression-free survival and overall ...
Cached Medicine Technology:Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 2Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 3Curis Announces Hedgehog and Wnt Antagonist Data Presentation at,AACR 4Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4
(Date:7/22/2014)... Texas (PRWEB) July 22, 2014 ... progress in almost every sphere of human anatomy. ... brought forth advancements that rendered the possibility of ... samples, including blood and tissues, in order to ... concerning congenital abnormality. Essentially, In-vitro Diagnostics (IVD) have ...
(Date:7/22/2014)... People who suffer long-term sleep problems after a divorce ... a new study suggests. Previous research has linked ... but few studies have examined the reasons for this ... according to the University of Arizona investigators. Their ... divorced for about 16 weeks. They reported on the ...
(Date:7/22/2014)... Dennis Thompson HealthDay Reporter ... therapies for autism focus on the child, but new ... treatments designed specifically for them. Mothers of autistic ... found they connected better with their child and felt ... University, in Nashville. , , "Interventions have, for good ...
(Date:7/22/2014)... a cup of coffee and sit down to read People ... last before you reach for another cup? Would you need ... A new study in the Journal of Consumer Research ... as coffee and aspirin lose their effectiveness when they engage ... how long it takes for products to wear off. For ...
(Date:7/22/2014)... Medicine (BUSM) and Boston Medical Center (BMC) have ... Violence Intervention Advocacy Program (VIAP)--an interventional program targeting ... violently injured youthswere less likely to retaliate for ... connections to caring, steady, supportive adults who helped ... reported in the journal Academic Emergency Medicine ...
Breaking Medicine News(10 mins):Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 2Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 3Health News:Global Molecular Diagnostics Market Report 2014 Edition Now Available at MarketReportsOnline.com 4Health News:Sleepless Nights After Divorce May Be Tied to Blood Pressure Rise 2Health News:Parents of Children With Autism Need Help, Too 2Health News:Parents of Children With Autism Need Help, Too 3Health News:Why do challenging tasks make consumers believe drugs wear off faster? 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3
... WASHINGTON, Aug. 31 As Congress prepares to return to ... least 102 rallies and other events in 20 states in ... insurance option. , , Events began Aug. ... returns to Washington, D.C.. They are taking place in California, ...
... , , , ... Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA sequencing ... in molecular diagnostics. , , "Until now, lack ... market, forcing laboratories to adopt number of alternative methods such as ...
... , , VENTURA, Calif., Aug. 31 ... than to receive." However, when the gift one is giving is ... with more than 97 percent organic aloe vera, receiving and giving ... Founded by Rinaldo and Lalla Brutoco, owners of the manufacturer ...
... , , TORRANCE, ... not be top-of-mind for empty-nesters. But keeping with the spirit of ... on nutrition lessons, take stock of your medicine cabinet and challenge ... can still take advantage of summer,s fresh produce, ensuring a consistent ...
... need for meds, helped some lose weight compared to low-fat ... Mediterranean diet, long touted as a healthy eating plan, may ... medications, as well as help them lose weight and lower ... Italian researchers who found that while 70 percent of people ...
... rare autoimmune condition, new report finds , MONDAY, Aug. 31 ... Kennedy still exerts a pull on medical sleuths nearly 50 ... by a U.S. Navy physician claims that Kennedy suffered from ... was diagnosed with as a young man. , In the ...
Cached Medicine News:Health News:'Let's Get it Done!' From Coast to Coast, USAction Affiliates Rally This Week for Quality, Affordable Health Care 2Health News:Cost Effective Solution for Patient Testing: Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy 2Health News:It's Better to Give Than to Receive 2Health News:It's Better to Give Than to Receive 3Health News:Change in Seasons: Ideal Time to Review Healthy Aging Habits 2Health News:Mediterranean Diet May Be Best for Type 2 Diabetes 2Health News:Mediterranean Diet May Be Best for Type 2 Diabetes 3Health News:JFK's Health Problems More Complex Than Thought 2Health News:JFK's Health Problems More Complex Than Thought 3
... Mammography has been FDA approved, and represents ... It is the first and only mammography ... - the highest available. SenoScan's larger field ... breast support is more comfortable and helps ...
... The P3000 heralds a new concept in pupillometry, ... infrared optical system developed for the P2000. ... in which we have paid particular attention to ... Our new system is extremely flexible, allowing you ...
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
... An easy-to-operate, semi-automatic urine analyzer that ensures ... your lab efficiency by reducing "hands on" ... makes it an ideal fit for work ... Criterion II Analyzer is designed for continuous ...
Medicine Products: